Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Gains from Investment Securities (2017 - 2025)

Inspire Medical Systems' Gains from Investment Securities history spans 9 years, with the latest figure at $8.5 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 463.61% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $10.1 million, up 566.97%, while the annual FY2025 figure was $10.1 million, 566.97% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $8.5 million at Inspire Medical Systems, up from -$950000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.9 million in Q4 2023 and bottomed at -$9.7 million in Q3 2022.
  • The 5-year median for Gains from Investment Securities is $422500.0 (2022), against an average of $1.6 million.
  • The largest YoY upside for Gains from Investment Securities was 8093.02% in 2022 against a maximum downside of 7617.05% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$296000.0 in 2021, then surged by 210.14% to $326000.0 in 2022, then soared by 4777.3% to $15.9 million in 2023, then crashed by 90.46% to $1.5 million in 2024, then soared by 463.61% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for INSP's Gains from Investment Securities are $8.5 million (Q4 2025), -$950000.0 (Q3 2025), and $1.9 million (Q2 2025).